DataSheet7_Effects of GLP-1 Receptor Agonists on Biological Behavior of Colorectal Cancer Cells by Regulating PI3K/AKT/mTOR Signaling Pathway.ZIP

Colorectal cancer (CRC) has become one of the top ten malignant tumors with a high incidence rate and mortality. Due to the lack of a good CRC screening program, most of the CRC patients are being transferred at the time of treatment. The conventional treatment cannot effectively improve the prognosis of CRC patients, and the target drugs can significantly prolong the overall survival of patients in the advanced stage. However, the use of single drug may lead to acquired drug resistance and various serious complications. Therefore, combined targeted drug therapy is the main alternative treatment with poor effect of single targeted drug therapy, which has important research significance for the treatment of CRC. Therefore, this study intends to culture CRC cell lines in vitro at the cell level and intervene with the GLP-1 receptor agonist liraglutide. The effects of liraglutide on the PI3K/Akt/mTOR signal pathway and CRC cell proliferation, cycle, migration, invasion, and apoptosis are explored by detecting cell proliferation, cycle, migration, invasion, and apoptosis and the expression of related mRNA and protein. The results showed that liraglutide, a GLP-1 receptor agonist, could block the CRC cell cycle, reduce cell proliferation, migration, and invasion and promote apoptosis by inhibiting the PI3K/Akt/mTOR signal pathway.

结直肠癌（Colorectal cancer, CRC）已成为发病率与死亡率均位居前列的十大恶性肿瘤之一。由于缺乏完善的CRC筛查方案，多数结直肠癌患者确诊时已发生转移。常规治疗无法有效改善结直肠癌患者的预后，而靶向药物虽可显著延长晚期患者的总生存期，但单一用药易引发获得性耐药及多种严重并发症。因此，针对单一靶向治疗效果欠佳的患者，联合靶向药物治疗成为主要备选方案，其在结直肠癌治疗领域具有重要的研究价值。
为此，本研究拟在细胞水平体外培养结直肠癌细胞系，并采用胰高血糖素样肽-1（GLP-1）受体（GLP-1 receptor）激动剂利拉鲁肽（liraglutide）进行干预。通过检测细胞增殖、周期、迁移、侵袭与凋亡情况，以及相关mRNA与蛋白的表达水平，探究利拉鲁肽对PI3K/Akt/mTOR信号通路（PI3K/Akt/mTOR signal pathway）及结直肠癌细胞增殖、周期、迁移、侵袭与凋亡的影响。
研究结果显示，GLP-1受体激动剂利拉鲁肽可通过抑制PI3K/Akt/mTOR信号通路，阻滞结直肠癌细胞周期、抑制细胞增殖、迁移与侵袭，并促进细胞凋亡。